TOP TEN perturbations for 1161_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1161_at
Selected probe(set): 200064_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1161_at (200064_at) across 6672 perturbations tested by GENEVESTIGATOR:

peptidoglycan study 1 / mock treated neonatal neutrophils

Relative Expression (log2-ratio):3.9879446
Number of Samples:3 / 3
Experimental peptidoglycan study 1
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery treated with peptidoglycan isolated from S. aureus (10 ug/ml) for 4 hours.
Control mock treated neonatal neutrophils
Healthy neonatal neutrophils with ≥ 99% purity isolated from cord blood samples collected after normal, full-term, vaginal delivery mock treated for 4 hours.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):2.7917967
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):2.747984
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

tumor supernatant activation study 3 / untreated memory CD4 T-cell sample

Relative Expression (log2-ratio):2.5942202
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control untreated memory CD4 T-cell sample
Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation.

T-helper activation study 1 (220min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.5728512
Number of Samples:2 / 2
Experimental T-helper activation study 1 (220min)
Alloantigen specific helper T-cells were stimulated for 220min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (200min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.5149403
Number of Samples:2 / 2
Experimental T-helper activation study 1 (200min)
Alloantigen specific helper T-cells were stimulated for 200min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (300min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.5137672
Number of Samples:2 / 2
Experimental T-helper activation study 1 (300min)
Alloantigen specific helper T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (340min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.4532719
Number of Samples:2 / 2
Experimental T-helper activation study 1 (340min)
Alloantigen specific helper T-cells were stimulated for 340min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (280min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.4468918
Number of Samples:2 / 2
Experimental T-helper activation study 1 (280min)
Alloantigen specific helper T-cells were stimulated for 280min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

Alzheimer's disease study 9 / normal pyramidal neuron (posterior cingulate)

Relative Expression (log2-ratio):-2.4253216
Number of Samples:9 / 13
Experimental Alzheimer's disease study 9
Cortical layer III pyramidal neurons of the posterior cingulate of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent.
Control normal pyramidal neuron (posterior cingulate)
Cortical layer III pyramidal neurons of the posterior cingulate of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density.